With Roche s Key PCR Patents Now Expired, What is Upshot for Genomics? | GenomeWeb

NEW YORK, March 29 (GenomeWeb News) - Roche's core PCR patents expired yesterday. The event will save millions of dollars a year in royalties for the companies and labs that rely on the technology, while creating a challenging environment for companies developing rival platforms.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.